Blackhawk Capital Partners LLC. Invests $928,000 in Becton, Dickinson and Company (NYSE:BDX)

Blackhawk Capital Partners LLC. acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,091 shares of the medical instruments supplier’s stock, valued at approximately $928,000.

A number of other large investors have also made changes to their positions in BDX. Brighton Jones LLC lifted its holdings in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares in the last quarter. E. Ohman J or Asset Management AB lifted its stake in shares of Becton, Dickinson and Company by 13.4% during the fourth quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier’s stock valued at $39,951,000 after buying an additional 20,859 shares during the period. Arete Wealth Advisors LLC acquired a new stake in Becton, Dickinson and Company during the third quarter worth approximately $767,000. Busey Bank boosted its position in Becton, Dickinson and Company by 3.8% during the fourth quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier’s stock worth $15,031,000 after acquiring an additional 2,399 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Becton, Dickinson and Company by 79.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after acquiring an additional 1,317,723 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $230.40 on Tuesday. The business’s fifty day moving average price is $232.96 and its 200 day moving average price is $233.25. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $66.16 billion, a P/E ratio of 38.27, a PEG ratio of 1.63 and a beta of 0.40.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. As a group, research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company declared that its board has authorized a share buyback program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be paid a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 1.81%. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 700 shares of the business’s stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total transaction of $159,593.00. Following the transaction, the director now owns 36,033 shares in the company, valued at $8,215,163.67. The trade was a 1.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Roland Goette sold 4,483 shares of the stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $221.01, for a total value of $990,787.83. Following the completion of the sale, the executive vice president now owns 24,345 shares of the company’s stock, valued at approximately $5,380,488.45. This trade represents a 15.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,544 shares of company stock valued at $2,370,309 over the last 90 days. Corporate insiders own 0.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Piper Sandler raised their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. Barclays raised their price target on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Finally, StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday, February 12th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $278.29.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.